SLC25A1 gene

Infants with this condition typically present with severe developmental delays, including an inability to sit or walk independently. Other common neurological signs include hypotonia (low muscle tone), seizures, and microcephaly (an abnormally small head size). As the child grows, they may experience progressive brain atrophy, which can lead to worsening motor skills, speech difficulties, and cognitive impairment. The brain is particularly vulnerable because the toxic buildup of hydroxyglutarate compounds damages neurons most severely in this organ. How does the SLC25A1 protein function in the cell, and why does its failure cause toxic buildup?::The SLC25A1 protein acts as a transporter in the mitochondria, moving citrate out of the energy-producing organelle and malate in. When the protein is defective due to a mutation, this exchange stops. This disruption prevents the normal metabolic flow, causing alternative metabolic pathways to become overactive. As a result, byproducts called D-2-hydroxyglutarate and L-2-hydroxyglutarate accumulate to toxic levels within the cells. These compounds interfere with normal cellular function and can trigger cell death, particularly in sensitive tissues like the brain. Is there a specific treatment or cure for combined D,L-2-hydroxyglutaric aciduria?::Currently, there is no cure for this condition, and treatment is primarily supportive and focuses on managing symptoms. This includes physical therapy to maintain mobility, occupational therapy for daily living skills, and anti-seizure medications if epilepsy is present. Research is ongoing to understand the metabolic pathways involved, but no specific therapy has yet been proven to reverse the neurological damage or lower the levels of toxic hydroxyglutarate compounds in the body. How is this specific form of 2-hydroxyglutaric aciduria diagnosed?::Diagnosis is typically confirmed through a combination of biochemical testing and genetic analysis. Urine and blood tests can detect elevated levels of both D-2-hydroxyglutarate and L-2-hydroxyglutarate, which distinguishes this condition from other forms of hydroxyglutaric aciduria that may only involve one form. Definitive diagnosis is achieved through genetic testing that identifies biallelic pathogenic variants in the SLC25A1 gene. Brain imaging, such as MRI, is also used to assess the extent of brain abnormalities and atrophy.